OTCMKTS:INNV - Innovus Pharmaceuticals Stock Price, Forecast & News

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) posted its quarterly earnings data on Thursday, November, 14th. The company reported ($0.81) EPS for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.40. The firm earned $5.76 million during the quarter, compared to the consensus estimate of $7.25 million. Innovus Pharmaceuticals had a negative return on equity of 1,611.96% and a negative net margin of 35.85%. View Innovus Pharmaceuticals' Earnings History.

Innovus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Innovus Pharmaceuticals.

1 analysts have issued 1-year price targets for Innovus Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Innovus Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 488.2% from the stock's current price. View Analyst Price Targets for Innovus Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovus Pharmaceuticals.

Media coverage about INNV stock has been trending somewhat positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innovus Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Innovus Pharmaceuticals.

Some companies that are related to Innovus Pharmaceuticals include Kaya (KAYS), Tetraphase Pharmaceuticals (TTPH), Tonix Pharmaceuticals (TNXP), Rexahn Pharmaceuticals (REXN), Novus Therapeutics (NVUS), Capricor Therapeutics (CAPR), Pivot Pharmaceuticals (PVOTF), Integrated BioPharma (INBP), DelMar Pharmaceuticals (DMPI), iCo Therapeutics (ICOTF), Sonoma Pharmaceuticals (SNOA), Earth Science Tech (ETST), X T L Biopharmaceuticals (XTLB), Reliv International (RELV) and Melinta Therapeutics (MLNT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovus Pharmaceuticals investors own include EEStor (ESU), Antares Pharma (ATRS), The Medicines (MDCO), Federal National Mortgage Association (FNMA), Frontier Communications (FTR), FedEx (FDX), Republic First Bancorp (FRBK), NVIDIA (NVDA), Pacific Premier Bancorp (PPBI) and Prospect Capital (PSEC).

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INNV stock can currently be purchased for approximately $0.85.

Innovus Pharmaceuticals has a market capitalization of $2.54 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.View Additional Information About Innovus Pharmaceuticals.

The official website for Innovus Pharmaceuticals is http://www.innovuspharma.com/.

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]